---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-136028"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:26:00.584699+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eloxx reports Q3 net loss of $9.9M; Phase 2 CF data on track for Q4 2021

## Summary
- Net loss of $9.9M ($0.11/share) vs $6.6M loss; R&D spending rose to $5.2M.
- Cash $52.4M as of Sep 30, 2021; expected to fund operations into Q1 2023.
- Entered debt facility with Hercules Capital for up to $30M, initial draw $12.5M.
- Appointed Dr. Ali Hariri as Chief Medical Officer.
- FDA Fast Track designation for ELX-02; Phase 2 monotherapy data expected Q4 2021.

## SEC filing metadata
- accession: 0001104659-21-136028
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465921136028/0001104659-21-136028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465921136028/tm2132381d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-136028
- JSON: https://secwatch.observer/filing/0001104659-21-136028.json
- Plain text: https://secwatch.observer/filing/0001104659-21-136028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.